Beta Bionics, Inc. (NASDAQ:BBNX) Insider Mark Hopman Sells 868 Shares

Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) insider Mark Hopman sold 868 shares of the stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $17.89, for a total value of $15,528.52. Following the sale, the insider now owns 34,132 shares in the company, valued at approximately $610,621.48. This represents a 2.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Beta Bionics Stock Performance

Beta Bionics stock traded up $1.49 during trading on Wednesday, reaching $19.45. The company had a trading volume of 821,154 shares, compared to its average volume of 501,945. Beta Bionics, Inc. has a 52 week low of $8.89 and a 52 week high of $24.50. The business's 50-day moving average is $12.75.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.01).

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on BBNX. Bank of America began coverage on Beta Bionics in a research note on Monday, February 24th. They issued a "buy" rating on the stock. Lake Street Capital began coverage on Beta Bionics in a research note on Monday, February 24th. They issued a "buy" rating and a $30.00 price target on the stock. Leerink Partnrs upgraded Beta Bionics to a "strong-buy" rating in a research note on Monday, February 24th. Robert W. Baird began coverage on Beta Bionics in a research note on Thursday, February 20th. They issued a "neutral" rating and a $20.00 price target on the stock. Finally, The Goldman Sachs Group began coverage on Beta Bionics in a research note on Friday, May 30th. They issued a "neutral" rating and a $16.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $23.13.

Institutional Investors Weigh In On Beta Bionics

Institutional investors and hedge funds have recently bought and sold shares of the business. Strs Ohio bought a new stake in Beta Bionics during the first quarter valued at about $29,000. Corebridge Financial Inc. bought a new stake in Beta Bionics during the first quarter valued at about $79,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Beta Bionics during the first quarter valued at about $95,000. MetLife Investment Management LLC bought a new stake in Beta Bionics during the first quarter valued at about $102,000. Finally, Deutsche Bank AG bought a new stake in Beta Bionics during the first quarter valued at about $148,000.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.